Type II Diabetes

In the U.S., type 2 diabetes currently affects 1 in 10 people and is expected to affect 1 in 3 people by 2050 1. Drug sales for type 2 diabetes were $23.4 billion in 2010, with an expected increase to $45 billion by 2020 2. Often, the absence of immediate noticeable treatment benefit leads to inadequate patient compliance. Unfortunately, severe manifestations of the disease, including blindness, kidney failure, neuropathy, and death, do not occur until years of improper treatment. Due to the staggering economic costs associated with diabetes ($245 billion in the U.S. alone 1). stakeholders are actively seeking treatments that improve compliance, and as a result, health outcomes.

GLP-1 receptor agonists are an increasingly utilized class of drugs for treating type 2 diabetes. There are currently 5 marketed drugs in this class, all of which require frequent injections, representing more than $2 billion in 2013 global sales. The market size for GLP-1 agonists is expected to reach nearly $8 billion by 2020 (17% CAGR 3).

1 American Diabetes Association, Fast Facts 2013
2 Decision Resources
3 Research and Markets

GLP-1 Agonists

Proven injectable type 2 diabetes treatment

Glp 1 agonists

  • Demonstrated weight-loss

    High GLP-1 levels increases satiety through delayed gastric emptying.

  • Effective glycemic control

    GLP-1 agonists enhance insulin sensitivity and insulin secretion.

  • Safe and effective treatment

    Exenatide was first approved for treating type 2 diabetes in 2005.

Problems With Current Treatment

Too Many Needles

Injection calendar

  • People don’t like injections

    Injections can be painful and are generally avoided when possible.

  • Frequent administration is required

    The short half-life of current GLP-1 agonists requires injections as often as twice-daily.

  • Poor patient compliance

    Inadequate compliance leads to reduced patient outcomes.

How We Solve It

Only One Implant Is Necessary

Implant calendar

  • Small device, simple insertion

    NanoPortal implantation can be performed in a quick, outpatient procedure.

  • Extended duration

    NanoPortal is being designed to last for durations of 3 months to 1 year.

  • Ensured compliance

    Implantation ensures continuous dosing for the duration of the treatment.

NanoPortal Platform